Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

World RNAi Market 2010Contract service = outsourced research/target validation projects Total = Projected worldwide RNAi revenues for 2010, in US dollars Source: Frost & SullivanScientists hunger for ...

Arrowhead Pharmaceuticals, Inc. ( ($ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc.

RNA interference (RNAi) offers a fast and easy system to study gene functions. However, the traditionally used small interfering RNAs (siRNAs) can exhibit pronounced and problematic off-target effects ...

In November 2025, Arrowhead Pharmaceuticals announced that the U.S. FDA approved REDEMPLO (plozasiran) as the first and only siRNA treatment for adults with familial chylomicronemia syndrome, ...

RNA interference (RNAi) takes place in the nuclei of human cells, according to a group from the University of Massachusetts Medical School. Tariq M. Rana, a coauthor on the study, says that until now ...